Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma

Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019;56(8):533–66.

Article  CAS  PubMed  Google Scholar 

Fukushima T, Uchiyama S, Tanaka H, Kataoka H. Hepatocyte Growth Factor Activator: A Proteinase Linking Tissue Injury with Repair. Int J Mol Sci. 2018;19(11).

Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45.

Article  PubMed  PubMed Central  Google Scholar 

Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):7–S19.

Article  Google Scholar 

Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem. 1995;270(2):603–11.

Article  CAS  PubMed  Google Scholar 

Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, et al. MET in gastric cancer with liver metastasis: the relationship between MET amplification and met overexpression in primary stomach tumors and liver metastasis. J Surg Oncol. 2018;117(8):1679–86.

Article  CAS  PubMed  Google Scholar 

Huang CY, Zhou QY, Hu Y, Wen Y, Qiu ZW, Liang MG, et al. Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis. Oncotarget. 2017;8(14):23459–69.

Article  PubMed  PubMed Central  Google Scholar 

Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, et al. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol. 2018;35:69–76.

Article  CAS  PubMed  Google Scholar 

Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget. 2016;7(45):72622–33.

Article  PubMed  PubMed Central  Google Scholar 

Neuzillet C, Couvelard A, Tijeras-Raballand A, de Mestier L, de Gramont A, Bedossa P, et al. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015;67(5):664–76.

Article  PubMed  Google Scholar 

Gao HF, Li AN, Yang JJ, Chen ZH, Xie Z, Zhang XC, et al. Soluble c-Met levels correlated with tissue c-Met protein expression in patients with Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(1):85–91.

Article  CAS  PubMed  Google Scholar 

Kim JH, Kim BJ, Kim HS. Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget. 2017;8(43):75478–87.

Article  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6.

Article  CAS  PubMed  Google Scholar 

Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of Tumours of the urinary system and male genital Organs-Part A: renal, Penile, and testicular tumours. Eur Urol. 2022;82(5):458–68.

Article  PubMed  Google Scholar 

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, et al. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 2012;110(1):76–83.

Article  PubMed  Google Scholar 

Erlmeier F, Feuchtinger A, Borgmann D, Rudelius M, Autenrieth M, Walch AK, et al. Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes. Histochem Cell Biol. 2015;144(2):147–56.

Article  CAS  PubMed  Google Scholar 

Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol. 2014;21(Suppl 4):584–90.

Article  Google Scholar 

Birks DK, Kleinschmidt-DeMasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK, et al. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2010;20(1):140–50.

Article  CAS  PubMed  Google Scholar 

Gao F, Li M, Xiang R, Zhou X, Zhu L, Zhai Y. Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis. Oncol Lett. 2019;17(5):4621–5.

CAS  PubMed  PubMed Central  Google Scholar 

Wang Q, Zhang Y, Zhang T, Han ZG, Shan L. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer. Onco Targets Ther. 2015;8:1971–7.

CAS  PubMed  PubMed Central  Google Scholar 

Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, et al. Hepatocyte growth Factor/cMET pathway activation enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 2015;75(19):4131–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silva Paiva R, Gomes I, Casimiro S, Fernandes I, Costa L. c-Met expression in renal cell carcinoma with bone metastases. J Bone Oncol. 2020;25:100315.

Article  PubMed  PubMed Central  Google Scholar 

Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting HGF/c-MET Axis in Pancreatic Cancer. Int J Mol Sci. 2020;21(23).

Kim ST, Hong JY, Park SH, Park JO, Park YW, Park N, et al. First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. Ther Adv Med Oncol. 2020;12:1758835920926796.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F et al. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. Int J Mol Sci. 2018;19(11).

Zambelli A, Biamonti G, Amato A. HGF/c-Met signalling in the Tumor Microenvironment. Adv Exp Med Biol. 2021;1270:31–44.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif